Soraya Rofagha, MD
Ophthalmology · Oakland, CANPI 1568687374
Payments from drug & device makers
Across 115 payments — averaging $17,385 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.2M
- Novartis$695K
- Regeneron$50K
- Carl Zeiss Meditec, Inc.$9K
- Eyepoint US, Inc.$2K
- AbbVie$881
- plus $863 from 8 others
What the payments were for
- Consulting fees$1,62055%
- Food & beverage$1,33845%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 70 | $1,242,498 |
| Novartis | 7 | $694,637 |
| Regeneron | 5 | $50,205 |
| Carl Zeiss Meditec, Inc. | 2 | $8,520 |
| Eyepoint US, Inc. | 1 | $1,620 |
| AbbVie | 4 | $881 |
| Astellas Pharma US Inc | 8 | $225 |
| Genentech USA, Inc. | 6 | $158 |
| ANI Pharmaceuticals, Inc. | 5 | $142 |
| Mallinckrodt Hospital Products Inc. | 2 | $140 |
| Alcon | 2 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Amgen | 1 | $27 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- YUTIQ$1,620
- Non-Covered Product$154
- BUPARLISIB$122
- ACTHAR$115
How this compares
$1,999,224 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 45 | $2,339 |
| Ketorolac Tromethamine | 33 | $1,052 |
| Atropine Sulfate | 18 | $570 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 39 | $394 |
| Latanoprost | 22 | $220 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $140 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Oakland
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.